| Room | Clyde Auditorium | Lomond Auditorium | Forth |
| 08:00 - 09:00 | Meet the Experts 1 Tumor Heterogeneity | Meet the Experts 2 Neurosurgical Precision Tools | Meet the Experts 3 Clinical Outcome Assessments |
| 08:00 | Temporal and spatial heterogeneity in gliomas | Continous dynamic mapping for removal of brain tumors in eloquent brain regions A. Raabe, Bern, CH | Patient-reported outcomes |
| 08:20 | Mouse models of glioma heterogeneity | TBA | Clincian-reported outcomes M. Jenkinson, Liverpool, UK |
| 08:40 | Clinical Implications of brain metastasis heterogeneity | DIPG S. Puget, Paris, FR | Performance outcomes
|
| 09:15 - 10:45 | Oral Session 1 Impact of tumor plasticity on experimental therapies | Oral Session 2 Exploring new radiation therapy technologies | Oral Session 3 Cellular origins of childhood brain tumors |
| Tumor plasticity from a neurosurgical perspective C. Watts, Birmingham, UK | Proton beam therapy for adult brain tumours: pros and cons G. Whitfield, Manchester, UK | TBA V. Hofestad, Boston, USA | |
| Impact of tumor plasticity on experimental therapies for brain metastases M. Valiente, Madrid, ES | Carbon ion therapy for brain tumours in theory and in practice S. Combs, Munich, DE | TBA L. Kutscher, Heidelberg, DE | |
| Impact of tumor plasticity on experimental therapies for gliomas W. Wick, Heidelberg, DE | TBA L. Tiberi, Trento, IT | ||
| 3 - 4 talks from submitted abstracts | 3 - 4 talks from submitted abstracts | 3 - 4 talks from submitted abstracts | |
| 11:30 - 13:00 | Plenary Session 1 Influence of brain tumors on neuronal circuits | ||
| GBM F. Winkler, Heidelberg DE | |||
| Pediatric and oligo M. Monje, Stanford, USA | |||
| Brain Metastasis Q. Zeng, Lausanne, CH | |||
| 3 - 4 talks from submitted abstracts | |||
| 14:45 - 16:15 | Oral Session 4 Multilayer Diagnostics | Oral Session 5 Rationalizing combination partners of immunotherapies | Oral Session 6 Quality of life |
| Integrated intraoperative diagnosis D. Orringer, Boston, USA | Combining immune checkpoint inhibitors with stereotactic radiosurgery: is it safe and does it work? G. Minniti, IT | Quality of life in follow-up (of children) K. Bull, Southampton, UK | |
| Proteomics for brain tumor diagnosis A. van Deimling, Heidelberg, DE | Combination of virotherapy and immunotherapy E.A. Chiocca, Boston, USA | Quality of life in follow-up (of adults) F. Boele, Leeds, UK | |
| Heterogeneity of myeloid cells in the CNS during helath and disease M. Prinz, Freiburg, DE | Combination of vaccines with checkpoint inhibitors V. Dutoit, Geneva, CH | ||
| 3 - 4 talks from submitted abstracts | 3 - 4 talks from submitted abstracts | 3 - 4 talks from submitted abstracts | |
| 16:30 - 18:00 | Oral Session 7 Functional imaging to enhance neurosurgical resection | Oral Session 8 Genome editing strategies for modelling brain tumors in mice | Oral Session 9 Cognitive functioning |
| TBA P. Plaha, Oxford, UK | The use of electroporation to dissect the biology of brain tumors P. Salomoni, Bonn, DE | Long-term treatment effects J. Wefel, Houston, USA | |
| Intra-operative MRI in neuro-oncology – a practical guide S. Mills, Liverpool, UK | New models of brain tumors M. Squatrito, Madrid, ES | Interventions for cognitive problems in non-CNS cancer patient
| |
| 3 - 4 talks from submitted abstracts | 3 - 4 talks from submitted abstracts | 3 - 4 talks from submitted abstracts |